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ABSTRACT: 
Background: 
Although the neutrophil-lymphocyte ratio (NLR) is prognostic in many oncological settings, its 
significance in the immunotherapy era is unknown.  Mechanistically, PD-1/PD-L1 inhibitors may alter 
NLR.  We sought to characterise NLR kinetics in patients with advanced solid tumours treated with 
PD-1/PD-L1 inhibitors. 
Methods: 
Electronic records of patients treated with PD-1/PD-L1 inhibitors on phase I trials across three sites 
were reviewed.  A high NLR (hNLR) was predefined as >5.  Univariate logistic regression models were 
used for toxicity, response analyses and Cox models for overall survival (OS) and progression-free 
survival analyses.  Landmark analyses were performed (cycle two, three). Longitudinal analysis of 
NLR was performed utilising a mixed effect regression model. 
Results: 
The median OS for patients with hNLR was 8.5 months and 19.4 for patients with low NLR, (HR= 
1.85, 95%CI 1.15-2.96, p=0.01). On landmark analysis, hNLR was significantly associated with inferior 
OS at all timepoints with a similar magnitude of effect over time (p<0.05).  On multivariate analysis, 
NLR was associated with OS (HR 1.06, 95% CI 1.01-1.11, p=0.01).  NLR did not correlate with 
increased immune toxicity.  Longitudinally, NLR correlated with response: NLR decreased by 0.09 
(95% CI: -0.15 to -0.02; p=0.01) per month in responders compared to non-responders. 
Conclusions: 
hNLR at baseline and during treatment is adversely prognostic in patients with advanced 
malignancies receiving PD-1/PD-L1 blockade.  Importantly, NLR reduced over time in responders to 
immunotherapy. Taken together, these data suggest that baseline and longitudinal NLR may have 
utility as a unique biomarker to aid clinical decision-making in patients receiving immunotherapy.     
Background: 
The advent of new cancer immunotherapeutics has led to renewed optimism in clinically meaningful 
progress to improve cancer outcomes for patients.  In particular, since a survival benefit was 
observed with ipilimumab, an immune checkpoint inhibitor (ICI), in patients with advanced 
melanoma (1), there has been an explosion in novel cancer immunotherapeutics.  The most 
successful molecules to date have been inhibitors of the programmed-death 1 (PD-1) - programmed 
death-ligand 1 (PD-L1) checkpoint, which have shown efficacy in multiple tumour types (2-5).  The 
success of these agents has launched a plethora of clinical trials in additional tumour types (6), in 
novel combinations to combat resistance (7), and increasingly in earlier treatment settings (8).  
Clinically, as these therapeutics enter standard practice, there will be a challenge, as the response 
and toxicity profiles of these agents differ substantially from those of traditional cytotoxics and 
targeted therapies (9, 10). 
 
The neutrophil-lymphocyte ratio (NLR) is a widely available blood-based clinical biomarker.  It is 
validated in numerous oncological settings (11), including the phase I setting (12), as both a 
prognostic marker (13) and a predictor of benefit for systemic therapy (14, 15).  Its clinical relevance 
is thought to stem from the fact that an elevated peripheral neutrophil count (the numerator for the 
NLR), is a marker of chronic inflammation which often leads to impaired immunity (16), whilst 
conversely the peripheral lymphocyte count (the denominator), is a hallmark of a healthy cytotoxic 
T-cell (CTL) response.  Increasingly, the interaction between the various populations of immune cells 
has been recognised as critical in forming the immune microenvironment, which forms the milieu 
through which the anti-cancer immune response occurs (17).  Moreover, as novel 
immunotherapeutics are licensed and enter clinical practice, new insights on the mechanisms 
underlying these interactions is emerging.  For instance, it is increasingly recognised that neutrophils 
directly suppress CTL activity via the release of cytokines (16), and that neutrophils stimulated by 
interferon-gamma are more likely to impair CTLs than other neutrophils.  Holistically, a lower NLR, 
which has consistently been shown to correlate with improved cancer outcomes (18), is thought to 
delineate a healthy host immune anti-tumour response.   
 
Nevertheless, there are several limitations with the NLR.  Historically, most studies correlating the 
NLR with survival outcomes in cancer have used the baseline NLR prior to treatment as a static 
measure (18).  However, the NLR appears to be dynamic and there is sparse data on the kinetics of 
the NLR response.  Some of the largest studies to date have been performed in the urology 
literature, which suggest a decreasing NLR correlates with improved outcomes in patients receiving 
anti-angiogenic therapies (19).  Other studies have shown that a decreasing NLR during 
chemoradiotherapy for glioblastoma is associated with improved survival (20), and that increases in 
NLR in patients undergoing palliative care are associated with inferior survival (21).  However, there 
is no published data regarding dynamic NLR kinetics with ICIs.  Dynamic changes in NLR pose a 
particular challenge with immunotherapy, as there is the possibility that a change in NLR may reflect 
a mechanistic response to therapy.  To date, initial studies have demonstrated that baseline NLR has 
prognostic value in melanoma patients treated with ipilimumab (22), and that baseline NLR has 
prognostic value in lung cancer patients treated with nivolumab (23).   
 
Moreover, given the emergence of the concept of pseudo-progression (10), there is an important 
clinical need to identify non-imaging based biomarkers that suggest response or progression on 
therapy.  Additionally, given the unique profile of immune toxicity (9), blood-based early biomarkers 
of emergent immune toxicity may also find a place in the clinical armamentarium.  The primary aim 
of this study was therefore, to evaluate the relationship of baseline NLR with response, survival and 
toxicity in patients with advanced solid tumours in patients treated in the phase I setting with 
antagonists of the PD-1/PD-L1 checkpoint.  The secondary aim was to evaluate the longitudinal 
kinetics of the NLR in these patients. The exploratory aim was to evaluate whether dynamic changes 
in the NLR were being driven by a change in the absolute lymphocyte count or the absolute 
neutrophil count. 
 
Methods: 
Study design: 
We conducted a retrospective multi-centre cohort study of consecutive patients with advanced solid 
tumours treated with PD-1/PD-L1 inhibitors in phase I clinical trials across three sites in the United 
Kingdom, Spain and Australia.  At least one dose of experimental agent needed to be received to be 
eligible for inclusion on this study.  Data collected included patient demographics and clinical data, 
haematology and biochemistry at baseline and prior to each cycle of therapy, toxicity data, 
concomitant medications, response data, date of last follow-up and date of death.  NLR at each cycle 
was calculated as the total neutrophil count divided by the total lymphocyte count.  A high NLR 
(hNLR) was defined as an NLR ≥ 5 consistent with the published literature (18, 23) and a low NLR 
(lNLR) as an NLR <5.  Adverse events (AEs) were graded according to the Common Terminology 
Criteria for Adverse Events (CTCAE v4.03) and were separated into immune-related and other 
toxicity.  Corticosteroid use, start date and indication were recorded.  Overall survival (OS) was 
calculated from date of first treatment to date of death and was censored at date of last follow-up.  
Progression-free survival (PFS) was calculated from first treatment to date of first progression by 
RECIST 1.1 and was censored at date of last follow-up.  Clinical benefit (CB) was defined as best 
response of complete response (CR)/partial response (PR) or stable disease (SD) by RECIST 1.1 (24), 
and was utilised over response rate as there is some evidence that SD is evidence of anti-tumour 
activity with immunotherapeutics (10).  Ethics approval for the study was obtained by each 
participating institution.  
 Statistical analysis: 
Fisher’s exact test and Wilcoxon rank-sum test were used respectively to describe the association of 
continuous and categorical variables with baseline NLR status.  Univariate logistic regression 
analyses were used to describe the association between NLR and response, toxicity and predefined 
established prognostic variables.  Kaplan-Meier plots present OS and PFS by baseline NLR status. 
Univariate and multivariate Cox models were used in OS and PFS analyses. Variables where p<0.1 in 
univariate analyses were selected for inclusion in multivariate analysis; baseline lymphocyte, ANC 
and NLR status were however excluded due to the relationship with baseline NLR.  Baseline albumin 
and LDH were excluded from multivariate analyses since these factors form part of the 
prognostically validated RMH score. The proportional hazards assumption was assessed using 
Schoenfeld residuals. A landmark analysis was performed for NLR at cycle two and three for both 
response and survival analyses.  Survival and logistic analyses were conducted using Stata v13.1. 
 
For the longitudinal analysis, a mixed effect regression model with per-patient random intercept and 
slope was applied to longitudinal NLR.  To enable better model fit NLR was transformed to be 
normally-distributed using a zero-skewness log transformation (transformed NLR=ln(NLR-0.29)). Due 
to the possible impact of corticosteroids on absolute neutrophil count, additional analyses were 
performed with data censored at steroid commencement date.  Additionally, a longitudinal analysis 
of absolute lymphocyte count was performed as an exploratory analysis, using R v3.3.2. 
 
Results: 
Between May 2014 and May 2017, 165 patients were treated with PD-1 and PD-L1 inhibitors.  
Baseline characteristics are displayed in Table 1.  Baseline characteristics were well balanced by 
baseline NLR status although patients with higher baseline NLR were more likely to have received 
previous radiotherapy treatment (p=0.03). Patients with higher baseline NLR were observed to have 
lower baseline haemoglobin (p<0.001) and lower baseline albumin (p<0.001). 
Overall, 79/165 (48%) achieved a CB.  Results from univariate logistic regression models of CB are 
shown in Table 2. On univariate logistic regression model for CB, there was no evidence that gender, 
age, PD-1 versus PD-L1 inhibitors, previous surgery or previous radiotherapy influenced response.  A 
higher baseline NLR was associated with lower odds of CB, driven largely by changes in the baseline 
lymphocyte count. On multivariate analyses, after accounting for differences in baseline 
haemoglobin, there was no evidence of a difference in CB by baseline NLR. However, baseline 
haemoglobin and NLR were highly correlated at baseline (Table 1). 
 
On landmark (Baseline, Cycle 2 and Cycle 3) logistic regression analyses for CB and univariate Cox 
models for OS, hNLR at was associated with a decreased odds ratio for clinical benefit at all 
timepoints and an increased risk of mortality on survival analysis, with a similar magnitude observed 
over time (Table 3). 
 
Median overall survival was 12.8 months (95% CI: 9.9-19.4).  Median survival for patients with low 
NLR (lNLR) was 19.4 months (95% CI 11.2-21.0) compared to 8.5 (95% CI 4.4-13.0) months for hNLR 
patients.  Univariate Cox models were performed for OS and PFS (Table 4 and Table 5) and the 
corresponding Kaplan-Meier plots are shown in Figure 1.  Baseline hNLR was associated with inferior 
OS (HR=1.85, 95% CI 1.15-2.96, p=0.01) but not with PFS (HR=1.14; 95% CI: 0.79-1.65; p=0.48). On 
multivariate analyses, baseline NLR and RMH score were associated with OS (Table 4); each unit 
increase in NLR lead to a 6% increase (HR=1.06; 95% CI=1.02-1.11; p=0.008) in the incidence of 
mortality. 
We also evaluated outcomes related to toxicity.  Previous surgery, baseline lymphocyte count and 
RMH score were associated with immune toxicity (see Table 6) but were not associated with grade 
3/4 immune toxicity. Only baseline ANC was associated with grade 3/4 immune toxicity. 
 
We subsequently analysed NLR over time.  A mixed-effects regression analysis with per patient 
random intercept was used to analyses changes in NLR during follow-up. Patients were censored at 
the start date of steroid use to exclude the confounding effect of steroids on total neutrophil count. 
A spaghetti plot of transformed NLR is shown in Figure 2. Overall, patients with CB had a lower log 
transformed NLR (p=0.03) at study entry (Coef=-0.39; 95% CI=-0.66 to -0.12; p=0.005 and Coef=-
0.39; 95% CI=-0.61 to -0.17; p<0.001 respectively) compared to patients with progressive disease 
(PD). There was no evidence for an overall change in transformed NLR during follow-up (Coef=-0.01; 
95% CI=-0.08 to 0.05; p=0.71).  
 
On exploratory analysis, however, there was evidence that the change in transformed NLR 
correlated with response (p=0.03). Patients with a RECIST response of CR/PR, had a -0.07 (95% CI=-
0.16 to 0.02; p=0.12) change in transformed NLR per month compared to patients with PD, while 
patients with SD did not (Coef=0.03; 95% CI=-0.05 to 0.11; p=0.49). Compared to the combined 
group of patients with SD and PD, patients with CR/PR had a -0.09 (95% CI: -0.15 to -0.02; p=0.01) 
change in transformed NLR per month. There was no evidence of a quadratic change in transformed 
NLR over time.  We applied the model to predict NLR by response category (see Figure 3), which 
suggests that responders typically have a reduction in NLR over time compared to non-responders 
and patients with stable disease. Finally, we attempted to delineate whether the dynamic changes in 
NLR over time were predominantly due to increased lymphocytes versus decreased neutrophils in 
responders.  Overall, there was no statistically significant evidence of changes in lymphocytes or 
neutrophils over time, suggesting that the observed change in NLR was due to a combination of 
changes in both populations of immune cells.   
 
Discussion 
The NLR is a widely validated clinical biomarker of prognosis applicable to several clinical settings.  
Its role in the immunotherapy era is undefined, although studies have shown that for melanoma 
patients treated with the CTLA-4 inhibitor, ipilimumab, the NLR retains its prognostic significance 
(22).  This study suggests that baseline NLR is correlated with clinical benefit and that it is 
significantly prognostic for overall survival in a population of patients with advanced solid tumours 
participating in phase I trials of PD-1/PD-L1 inhibitors.  Although a significant effect was not 
observed in PFS analyses, given the relative clinical significance of OS and the difficulties in assessing 
PFS in patients treated with immunotherapeutics given novel patterns of response (10), the 
significance of the OS data cannot be understated.   
 
Moreover, given the evident potential impact of immunotherapy on the dynamic NLR, this is the first 
study, to our knowledge, analysing the dynamic kinetics of the NLR.  Firstly, it was reassuring to note 
that the NLR retained its broadly prognostic significance over time in the landmark analysis, with a 
consistent effect size temporally.   This continued effect was subsequently explained by the mixed-
effects regression analysis which showed that responding patients had a consistent decrease in the 
NLR over time, whereas patients with stable disease or progression did not.  This analysis was not 
coloured by steroid utilisation artificially increasing the neutrophil count in patients with steroid-
responsive disease-related symptoms or toxicity as data was censored at steroid commencement 
date. This is the first study to report this finding in patients receiving PD-1/PD-L1 inhibitors.  
Importantly, as has been recognised elsewhere (25), the escalating costs of immunotherapy to the 
overall burden of healthcare costs is unsustainable, yet in this very context, clinicians are struggling 
to cease potentially ineffectual therapies due to the perceived risk of missing pseudo-progression 
(26).  With this additional data in mind, it may be useful for clinicians to recognise that a 
combination of a disease progression by traditional radiographic response criteria and a rising or 
high NLR represents a clinical scenario with a low likelihood of benefit from continued therapy.  
Moreover, the negative finding that clinical variables and the NLR are not predictive of treatment 
emergent toxicity is noteworthy. 
 
The results of this study also pose further scientific questions.  Significantly, the mechanism by which 
dynamic changes in NLR were correlated with improved prognosis was not explained purely by an 
increase in the absolute lymphocyte count alone, as might be inferred given the mechanism of 
action of PD-1 inhibitors.  Nor was it explained by a decrease in the neutrophil count, but rather, by 
a change in both subsets.  These findings suggest that the change in NLR observed in responders 
may reflect broader changes in the tumour microenvironment, the exact nature of which remains to 
be further elucidated. 
 
There are several limitations to the study.  Firstly, this study was limited to patients with advanced 
solid tumours participating in phase I clinical trials.  Although the results may not be generalisable to 
a general oncology population, there was a wide range of solid tumours represented.  Moreover, the 
fact that this was a multi-institutional, multi-national collaboration of phase I trial centres, ensured 
high quality and complete data was maintained prospectively, with minimal missing data skewing 
the analysis.  Moreover, given the retrospective nature of the study, if the dynamic NLR is to shift 
clinical practice to be utilised as an additional clinical biomarker in decision-making, this data needs 
to be validated, ideally from a prospectively collected independent dataset. 
 As PD-1 inhibitors increasingly enter routine clinical practice, the importance of readily available 
clinical biomarkers to assist clinical decision making is paramount. This study shows that the NLR is 
significantly prognostic on overall survival outcomes on patients with advanced solid tumours 
participating in phase I trials of PD-1/PD-L1 inhibitors.  Furthermore, it is the first study to suggest 
that responding patients have a decline in their longitudinal NLR over time, whereas patients who 
fail to respond do not, a fact which may assist clinical decision making.   
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Table 1: Baseline characteristics 
 
 Baseline NLR≤5 Baseline NLR>5  
Variable N % N % p-value 
Total 110 55  
Gender      
   Female 46 42 28 51 
0.32 
   Male 64 58 27 49 
Treatment type      
   PD1 99 90 52 95 
0.39 
   PD-L1 11 10 3 5 
Tumour Type      
   Gastrointestinal 14 13 10 18 
0.25 
   Lung 38 35 13 24 
   Mesothelioma 15 14 9 16 
   Gynaecological 15 14 14 25 
   Central nervous system 2 2 0 0 
   Genitourinary 7 6 4 7 
   Other 19 17 5 9 
Previous Surgery      
   No 61 55 32 58 
0.87 
   Yes 49 45 23 42 
Previous Radiotherapy      
   No 73 66 26 47 
0.03 
   Yes 37 34 29 53 
 Median Q1-Q3 Median Q1-Q3  
Age (years) 62 57-70 61 49-71 0.30 
Baseline Hb (g/L) 121 113-132 110 102-121 <0.001 
Albumin (g/L) 38 34-41 34 30-38 <0.001 
Log10 LDH 2.6 2.3-2.8 2.5 2.2-2.7 0.09 
 
 
  
Table 2: Univariate and multivariate regression analysis for clinical benefit (CB) 
 
Variables Uni OR 95% CI p-value Multi 
OR 
95% CI p-value 
Male vs. female 1.04 0.56-1.93 0.89 - - - 
PD-L1 inhibitor vs. PD-1 
inhibitor 
1.50 0.50-4.54 0.47 - - - 
Previous surgery (yes vs. 
no) 
0.86 0.47-1.60 0.64 - - - 
Previous radiotherapy (yes 
vs. no) 
0.85 0.46-1.59 0.61 - - - 
Age (by decade) 1.04 0.83-1.30 0.75 - - - 
Baseline NLR 0.91 0.83-0.99 0.04 0.93 0.85-1.02 0.11 
Baseline ANC 0.96 0.86-1.07 0.50 - - - 
Baseline Lymph 1.67 0.93-3.00 0.08 - - - 
Baseline Hb (g/L) 1.03 1.01-1.05 0.008 1.02 1.00-1.04 0.04 
Albumin (g/L) 1.09 1.02-1.15 0.008 - - - 
Log10 LDH (U/L) 0.51 0.19-1.33 0.17 - - - 
RMH Score 0.71 0.50-1.01 0.06 0.74 0.52-1.07 0.11 
 
  
Table 3: Landmark analysis for NLR for CB and OS. 
 
  Landmark analysis for CB Landmark analysis for OS 
NLR 
timepoint 
N OR 95% CI p-value HR 95% CI p-value 
Baseline 165 0.91 0.83-0.99 0.04 1.07 1.03-1.11 0.001 
Cycle 2 150 0.91 0.82-1.00 0.05 1.06 1.01-1.11 0.01 
Cycle 3 129 0.88 0.79-0.98 0.02 1.06 1.01-1.11 0.02 
 
  
Table 4: Univariate and multivariate Cox models for OS 
 
Variables Uni HR 
for OS 
95% CI p-value Multi HR 
for OS 
95% CI p-value 
Gender       
Male vs. female 0.95 0.59-1.54 0.85 - - - 
Treatment       
PD-L1 inhibitor vs. PD-
1 inhibitor 
1.44 0.62-3.35 0.40 - - - 
Previous Surgery (yes 
vs. no) 
      
Yes 0.99 0.61-1.58 0.95 - - - 
Previous 
Radiotherapy (yes vs. 
no) 
      
 0.95 0.58-1.53 0.83 - - - 
Baseline NLR>5       
hNLR vs lNLR 1.85 1.15-2.96 0.01 - - - 
       
Age (10 Years) 1.05 0.89-1.25 0.54 - - - 
Baseline NLR 1.07 1.03-1.11 0.001 1.06 1.02-1.11 0.008 
Baseline ANC 1.05 0.99-1.11 0.13 - - - 
Baseline Lymph 0.64 0.40-1.04 0.07 - - - 
Baseline Hb 0.98 0.96-0.99 0.01 0.99 0.97-1.00 0.09 
Albumin 0.97 0.92-1.01 0.13 - - - 
Log10 LDH 3.07 1.41-6.66 0.005 - - - 
RMH Score 1.40 1.07-1.83 0.02 1.34 1.01-1.77 0.04 
 
  
Table 5: Univariate Cox models for PFS 
 
Variables Uni HR 
for PFS 
95% CI p-value 
Gender    
Male vs. female 0.99 0.70-1.41 0.97 
Treatment    
PD-L1 inhibitor vs. PD-
1 inhibitor 
0.91 0.47-1.73 0.76 
Previous Surgery (yes 
vs. no) 
   
Yes 1.17 0.82-1.66 0.38 
Previous 
Radiotherapy (yes vs. 
no) 
   
Yes 1.07 0.75-1.52 0.72 
Baseline NLR>5    
hNLR vs lNLR 1.14 0.79-1.65 0.48 
    
Age (10 Years) 0.96 0.85-1.09 0.55 
Baseline NLR 1.03 0.99-1.06 0.17 
Baseline ANC 1.02 0.97-1.08 0.39 
Baseline Lymph 0.96 0.69-1.33 0.82 
Baseline Hb 0.99 0.98-0.99 0.01 
Albumin 0.95 0.92-0.98 0.005 
Log10 LDH 0.88 0.48-1.61 0.68 
RMH Score 1.09 0.89-1.33 0.41 
 
  
Table 6: Univariate logistic regression models for any grade and G3/G4 immune toxicity 
 
Variables Uni OR 
for any 
grade 
95% CI p-value Uni OR 
for G3/4 
95% CI p-value 
Gender       
Male vs. female 0.81 0.43-1.51 0.50 0.78 0.32-1.93 0.60 
Treatment       
PD-L1 inhibitor vs. PD-
1 inhibitor 
0.65 0.21-2.04 0.47 1.08 0.22-5.16 0.93 
Previous Surgery (yes 
vs. no) 
      
Yes 1.93 1.03-3.64 0.04 1.62 0.66-4.00 0.30 
Previous 
Radiotherapy (yes vs. 
no) 
      
Yes 1.25 0.67-2.36 0.49 0.59 0.20-1.69 0.33 
Baseline NLR>5       
hNLR vs lNLR 0.57 0.29-1.12 0.10 1.18 0.46-3.01 0.73 
       
Age (10 Years) 1.04 0.83-1.30 0.75 1.36 0.91-2.03 0.13 
Baseline NLR 0.98 0.91-1.05 0.58 1.06 0.98-1.15 0.13 
Baseline ANC 1.05 0.94-1.17 0.42 1.14 1.01-1.30 0.04 
Baseline Lymph 1.95 1.07-3.54 0.03 1.00 0.44-2.27 0.99 
Baseline Hb 1.01 0.99-1.03 0.32 1.00 0.97-1.02 0.82 
Albumin 1.06 1.00-1.12 0.07 1.02 0.93-1.11 0.73 
Log10 LDH 0.89 0.35-2.31 0.82 0.72 0.17-3.00 0.65 
RMH Score 0.64 0.45-0.92 0.02 0.89 0.55-1.47 0.66 
 
 
  
Figure 1: Kaplan-Meier survival plots for OS and PFS 
 
 
 
  
Figure 2: Longitudinal plot of natural log of NLR over time by RECIST response status 
 
 
  
Figure 3: Predicted NLR over time according to RECIST response status 
 
 
 
